Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntuitive Investment Group Regulatory News (IIG)

Share Price Information for Intuitive Investment Group (IIG)

Share Price is delayed by 15 minutes
Get Live Data
297.00    -8.00 (-2.62%)
Bid:
290.00
Ask:
304.00
Spread: 14.00 (4.828%)
Market Cap: £710.74m
IIG Live PriceLast checked at - London Stock Exchange

Intraday Intuitive Investment Group Share Chart

Form 8.3 - Peter Kershaw

Today 10:00

RNS Number : 5860K
Intuitive Investments Group plc
01 July 2026
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Peter JC Kershaw

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Intuitive Investments Group plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

30.06.26

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

 

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Ordinary Shares of £0.10 each

 

 

Interests

Short positions

 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

15,555,734

6.47

 

 

(2) Cash-settled derivatives:

 

 

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

 

TOTAL:

15,555,734

6.47

 

 

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit (GBP)

Ordinary Shares of £0.10 each

Sale

 

1,000,000

3.05

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

1 July 2026

Contact name:

Peter Kershaw

Telephone number*:

 

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETSSUSAFEMSESW
Date   Source Headline
7th Nov 20222:05 pmRNSSecond Price Monitoring Extn
7th Nov 20222:00 pmRNSPrice Monitoring Extension
5th Aug 20227:00 amRNSInvestment in PneumoWave Limited
26th May 20227:00 amRNSUpdate on Sanondaf
25th May 20227:00 amRNSHalf-year Report
20th Apr 202211:13 amRNSDispensation from Rule 9 of the Code
4th Apr 202211:13 amRNSTotal Voting Rights
8th Mar 20223:39 pmRNSHolding(s) in Company
2nd Mar 20227:00 amRNSSubscription
25th Feb 202212:11 pmRNSInvestment & Appointment of Non-Executive Chair
14th Feb 202212:59 pmRNSChange of Registered Office
14th Feb 20227:00 amRNSInvestment in Ocutec Limited
24th Jan 20228:45 amRNSDirector Dealing
30th Dec 202110:58 amRNSResult of AGM
20th Dec 20217:00 amRNSChange of Registered Office
6th Dec 20217:00 amRNSFinal Results and Notice of AGM
29th Nov 20217:00 amRNSChange of Adviser
5th Nov 202110:12 amRNSHolding(s) in Company
28th Oct 20211:38 pmRNSNotice of Results
15th Oct 20218:01 amRNSLight Science Technologies Holdings - Floatation
12th Oct 20219:48 amRNSLight Science Technologies - Intention To Float
20th Sep 20218:04 amRNSLight Science Technologies Holdings - update
15th Sep 20217:00 amRNSInvestment in Momentum Bioscience Limited
20th Aug 20213:40 pmRNSDirector Dealing
29th Jun 202110:56 amRNSInvestment in Midatech Pharma PLC
2nd Jun 20217:00 amRNSInterim report
28th May 20212:18 pmRNSInvestment in Trellus Health plc
4th May 20217:00 amRNSInvestment in The Electrospinning Company Limited
9th Apr 202111:01 amRNSIssue of Shares and Total Voting Rights
1st Apr 20217:00 amRNSInvestment in Axol Bioscience Ltd
31st Mar 20214:18 pmRNSInvestment in Altair
31st Mar 202112:00 pmRNSInvestment in CardiNor AS
17th Mar 20217:00 amRNSInvestment in Polarean Imaging plc
16th Mar 20217:00 amRNSInvestment in Micrima Limited
1st Mar 20217:00 amRNSInvestment in Shield Therapeutics plc
22nd Feb 20217:00 amRNSInvestment in Yourgene Health plc
12th Feb 202111:41 amRNSProposed Investment in Kromek Pharma plc
8th Feb 202111:08 amRNSHolding(s) in Company
3rd Feb 20217:00 amRNSProposed Investment in Evgen Pharma plc
29th Jan 20217:00 amRNSPortfolio company BioQ Pharma receives CE mark
25th Jan 20217:00 amRNSProposed Investment in Microsaic Systems plc
21st Jan 20214:41 pmRNSSecond Price Monitoring Extn
21st Jan 20214:35 pmRNSPrice Monitoring Extension
21st Jan 20217:00 amRNSInvestment in BioQ Pharma
11th Jan 20217:00 amRNSPre-IPO Investment in Light Science Technologies
14th Dec 20207:00 amRNSAIM Admission & First Day of Dealings
17th Jul 200610:58 amPRNDirector/PDMR Shareholding
30th Jun 200610:19 amPRNIssue of Equity
20th Jun 20063:08 pmPRNDirector/PDMR Shareholding
2nd Jun 200612:20 pmPRNCorrection : Holding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.